# US 2010/0168027 A1 · Bpc-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168027 A1
- Document ID: US20100168027A1
- Status: Published application
- Kind: A1
- Application number: 12/718,821
- Filed: 2010-03-05
- Published: 2010-07-01
- Earliest claimed: 1998-08-10
- Assignees: Agensys, Inc.
- Inventors: Daniel E. AFAR; Rene S. Hubert; Kahan Leong; Arthur B. Raitano; Douglas C. Saffran; Aya Jakobovits
- Web page: https://patentgrep.com/patent/US20100168027A1

## CPC

- C07K 14/47: from mammals
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 35/00: Antineoplastic agents
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2319/02: containing a signal sequence
- C12N 2799/026: where the vector is derived from a baculovirus
- C12N 2799/027: where the vector is derived from a retrovirus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described is a novel gene and its encoded secreted tumor antigen, termed BPC-1, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express BPC-1, particularly including prostate cancer and bladder cancer. In human normal tissues, BPC-1 is only expressed in certain tissues of the brain. However, BPC-1 is expressed at high levels in prostate cancer cells and is also expressed in bladder cancer cells. The structure of BPC-1 includes a signal sequence and a CUB domain. BPC-1 protein is secreted. Preliminary experimental evidence suggests that BPC-1 is directly involved in oncogenesis or maintenance of the transformed phenotype of cancer cells expressing BPC-1. BPC-1 also appears to bind specifically to a cellular protein expressed in prostate cancer cells and other cells.

## Claims

### Claim 1

A purified polypeptide, comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 2

A composition comprising a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 3 (depends on 2)

The composition of claim 2, further comprising a pharmaceutically acceptable excipient.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the excipient is a carrier or a preservative.

### Claim 5 (depends on 2)

The composition of claim 2, further comprising an adjuvant.

### Claim 6 (depends on 2)

The composition of claim 2, wherein the composition is adapted for intravenous, parenteral, intraperitoneal, intramuscular, intratumor, intradermal, intraorgan, or orthotopic administration.

### Claim 7

An isolated antibody or antigen-binding fragment thereof that immunospecifically binds to an epitope on a protein comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 8 (depends on 7)

The antibody or fragment thereof of claim 7, which is polyclonal.

### Claim 9 (depends on 7)

The antibody or fragment thereof of claim 7, which is monoclonal.

### Claim 10 (depends on 9)

The antibody or fragment thereof of claim 9, which is a recombinant protein.

### Claim 11 (depends on 10)

The antibody or fragment thereof of claim 10, which is a single chain monoclonal antibody.

### Claim 12 (depends on 7)

The antibody or fragment thereof of claim 7, which is a human antibody.

### Claim 13 (depends on 7)

The antibody or fragment thereof of claim 7, which is labeled with a cytotoxic agent.

### Claim 14 (depends on 13)

The antibody or fragment thereof of claim 13, wherein the cytotoxic agent is a radioactive isotope or chemotherapeutic agent.

### Claim 15 (depends on 14)

The antibody or fragment thereof of claim 14, wherein the radioactive isotope is selected from the group consisting of 212Bi, 131In, 125I, 90Y, 186Re, and 188Re.

### Claim 16 (depends on 14)

The antibody or fragment thereof of claim 14, wherein the chemotherapeutic agent is selected from the group consisting of tricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethiduim bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphteria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, arbrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, and glucocorticoid.

### Claim 17 (depends on 7)

The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof further comprises a pharmaceutically acceptable carrier.

### Claim 18 (depends on 9)

A hybridoma that produces the monoclonal antibody of claim 9.
